At the association's annual meeting, Klaus-Peter Behr, Chairman of EMAV, welcomed two new EMAV members, Syva from Spain and FILAVIE from France.
Syva is a family owned animal health business, based in León, Spain. The company is dealing with vaccines - toxoid bacterial and viral vaccines, live and inactivated (including autogenous vaccines) - and with Betalactam antibiotics mainly. Core disease areas are respiratory, gastrointestinal and vector-borne diseases especially in cattle, swine and small ruminants. Syva was accepted as an ordinary EMAV member.
FILAVIE, based in Sevremoine in France, is part of Ceva autogenous vaccines group and one manufacturing site next to those in the UK, Germany, Canada and the US and with Ceva-Biovac another one in France. FILAVIE has a focus on viral vaccine production and is a dedicated site for the development and manufacturing of custom-made viral vaccines – for the targeted prevention of emerging, endemic, orphan diseases and for minor species. As part of CEVA, FILAVIE was accepted as an associated member of EMAV.
Following the EMAV statutes members took the opportunity to elect new EMAV Board members at the General Assembly. Klaus-Peter Behr (GE) and Maarten de Gussem (Poulpharm/BE) were re-elected. Newly elected to the Board was Jean-Charles Tissot (Ceva/FR). The Executive Board was completed by Astrid Weiss (AGES/AT) and Javier Sanz Martin (Syva/ES), who will continue for another year. Klaus-Peter Behr was re-elected as Chairman and Maarten de Gussem as Deputy Chair by the EMAV members.
EMAV members and Managing Director Dr. Gerfried Zeller welcomed the election of a board of such competent and experienced experts in the field of autogenous vaccines.